Herbalife (HLF) Is Up 6.2% After Analyst Upgrade on New Wellness Launches Has Sentiment Turned?

• In late November 2025, Argus Research upgraded Herbalife to a 'Buy' rating after the company presented at the Furey Hidden Gems Corporate Access Conference, citing expected revenue growth from new wellness products HL/Skin and MultiBurn.
• This analyst upgrade ended a three-year period of revenue decline expectations for Herbalife, highlighting renewed optimism around the company's product innovation pipeline.
• We'll explore how renewed revenue growth prospects from product launches may influence Herbalife's overall investment narrative.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Herbalife Investment Narrative Recap

To invest in Herbalife right now, you need to believe the company can successfully capitalize on new wellness products like HL/Skin and MultiBurn to reverse years of softening sales, while keeping risks from regulatory scrutiny and evolving consumer preferences at bay. The recent Argus Research upgrade points to product launches as the leading short-term catalyst for growth, though ongoing global skepticism toward multi-level marketing remains the most pressing concern. For now, the analyst upgrade highlights renewed confidence, but the long-term impact will depend on sustained product momentum and regulatory outcomes.

Of the recent company developments, Herbalife's October opening of its new Center of Excellence in Quality Control stands out because it directly supports the innovation of products like HL/Skin and MultiBurn. This advanced facility brings together R&D and quality control under one roof, further supporting the company’s pipeline of wellness innovations that are central to its growth story this year.

Yet, despite all the optimism around new products, there remains the question of how Herbalife will manage escalating regulatory pressures...

Read the full narrative on Herbalife (it's free!)

Herbalife's narrative projects $5.6 billion revenue and $152.6 million earnings by 2028. This requires 4.4% yearly revenue growth and a decrease of $172.4 million in earnings from the current $325.0 million.

Uncover how Herbalife's forecasts yield a $9.67 fair value, a 24% downside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have shared 9 fair value estimates for Herbalife, spanning from US$2.06 to US$21.33 per share. While bulls see upside in recent product launches, many are openly questioning the long-term effects of changing regulations on the business, be sure to compare these views before making your own decision.

Explore 9 other fair value estimates on Herbalife - why the stock might be worth less than half the current price!

Build Your Own Herbalife Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Herbalife research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Herbalife research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Herbalife's overall financial health at a glance.

No Opportunity In Herbalife?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.
• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com